Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular…

By Donavan T. Cheng, Talia Mitchell, A. Zehir, Ronak H. Shah, R. Benayed, Aijazuddin Syed, Raghu Chandramohan, Z. Liu, H. Won, Sasinya N. Scott and 18 more. Journal of Molecular Diagnostics, 2015

1,971 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/4272886d3a15fe67ee758c2ceffcd3e46a44dee6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations (2016, background): “The Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) [15], for example, has carried out the targeted deep sequencing of all exons and selected introns of 341 key cancer genes of thousands of tumors every year…”
Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells (2020, neutral): “This breadth of information contrasts with the fewer genes included in current cancer mutation panels such as MSK-IMPACT or FoundationOne CDx (468 and 324 genes, respectively), which were designed to be queried manually by a physician (Cheng et al., 2015; Harris, 2017).”
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (2018, methodology): “The MSK-IMPACT assay was performed as previously described.(14) Briefly, DNA was extracted from tumors and patientmatched blood samples.”
Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and impacts clinical outcome (2017, methodology): “…assay, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), encompassing the full protein-coding sequence of 341 (and more recently, 410) cancer-associated genes, for prospective clinical sequencing of matched tumor and blood DNA (Cheng et al., 2015).”
The long tail of oncogenic drivers in prostate cancer (2018, neutral): “Significantly mutated genes (SMGs) fell within two different categories: 1) q values less than 0.1 and altered in at least 10 samples, 2) q values between 0.1 and 0.25, altered in 10 samples, and in known cancer genes 5,38 .”
Precision Cancer Medicine: Challenges and Opportunities (2019, methodology): “1975–1977: The first generation Sanger DNA sequencing method was invented [42, 43], which was further optimized and automated over the following decades [10, 12].”
FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing (2016, methodology): “Figure 7 shows a FACETS application to the MSKIMPACT clinical sequencing platform, a hybridization capture-based next-generation sequencing assay for targeted deep sequencing of all exons and selected introns of 410 key cancer genes in FFPE tumor samples (13) .”